Indian vaccine has shown ‘least side-effects’

Phase III trials of Covaxin begin at Rohtak today

Tribune Web Desk

Updated At : 12:32 PM Nov 19, 2020 IST

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits

Yearly Premium ₹999 ₹349/Year

Yearly Premium $49 $24.99/Year

Rohtak, November 18

India is going to be amongst the pioneering nations of the world with the development of its indigenous Covid vaccine Covaxin in the near future. Indian Covid-19 vaccine is unique as it has shown minimum side-effects.

This was stated by Dr OP Kalra, Vice Chancellor of Pt Bhagwat Dayal Sharma University of Health Sciences, Rohtak, while addressing a news conference here today.

Professor Kalra disclosed that the third phase of the clinical human trials of Covaxin would begin at the Rohtak PGIMS on November 19. — TNS

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is run by a trust comprising five eminent persons as trustees.

The Tribune, the largest selling English daily in North India, publishes news and views without any bias or prejudice of any kind. Restraint and moderation, rather than agitational language and partisanship, are the hallmarks of the newspaper. It is an independent newspaper in the real sense of the term.

The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).

Remembering Sardar Dyal Singh Majithia

Designed and developed by : SORTD

Unlock Exclusive Insights with The Tribune Premium

Suggested Articles